Cibenzoline is a class I antiarrhythmic drug used to manage ventricular and supraventricular tachycardias by blocking cardiac sodium channels, slowing conduction, and stabilizing heart rhythm. Developed in Japan in the 1970s, it offered a targeted alternative to older antiarrhythmics, reducing arrhythmia episodes while minimizing some adverse effects. Orally absorbed, metabolized in the liver, and primarily excreted via the kidneys, cibenzoline has become an important option in cardiology, particularly for patients with structural heart disease or intolerance to other antiarrhythmics. Its development marked a step forward in safer, more effective, and patient-specific rhythm management.
Image
